MA
BCTXL

MYDA Advisors’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

MYDA Advisors’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Buy
+200,000
New +$212K 0.03% 139

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

MYDA Advisors's BCTXL Position: Q1 2026 in Review

MYDA Advisors opened a new position in BriaCell Therapeutics Warrant (BCTXL) in Q1 2026: 200,000 shares worth $206K. The stake represents 0.03% of the portfolio and ranks #139 among its holdings.

15 funds tracked by Wall St. Rank hold BCTXL as of Q1 2026.

  • MYDA Advisors held 200,000 shares of BriaCell Therapeutics Warrant worth $206K as of Q1 2026.
  • BriaCell Therapeutics Warrant was a new MYDA Advisors position in Q1 2026.
  • BriaCell Therapeutics Warrant made up 0.03% of MYDA Advisors's portfolio in Q1 2026, its #139 holding.
  • 15 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q1 2026.

Based on MYDA Advisors's 13F filing for Q1 2026, filed 14 May 2026.